Global Kidney Cancer Therapeutics & Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Cancer Type;

Clear cell RCC, Papillary RCC, Chromophobe RCC, Urothelial carcinoma/Transitional Cell Carcinoma, Other Kidney Cancers (Wilms tumor, Renal sarcoma and Collecting duct RCC.)

By Component;

Drugs - Therapeutic Class[Targeted Therapy, Immunotherapy, and Other Therapeutic Class], - By Pharmacologic Class[Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors and Cytokine Immunotherapy (IL-2)], - Diagnostics[Biopsy, Imaging Tests, Blood Tests and Other Diagnostics.]

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn979530336 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Kidney Cancer Therapeutics & Diagnostics Market (USD Million), 2021 - 2031

In the year 2024, the Global Kidney Cancer Therapeutics & Diagnostics Market was valued at USD 8,001.80 million. The size of this market is expected to increase to USD 18,023.79 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 12.3%.

The global kidney cancer therapeutics and diagnostics market encompasses a comprehensive range of pharmaceuticals, biologics, diagnostic tests, and imaging techniques used in the diagnosis, treatment, and management of kidney cancer, also known as renal cell carcinoma (RCC). This market includes targeted therapies, immunotherapies, surgery, radiation therapy, imaging modalities, and biomarker tests aimed at improving patient outcomes and quality of life.

Several factors contribute to the growth and dynamics of the global kidney cancer therapeutics and diagnostics market. Firstly, the increasing incidence and prevalence of kidney cancer worldwide drive the demand for effective diagnostic tools and therapeutic interventions. Risk factors such as smoking, obesity, hypertension, and exposure to carcinogens contribute to the rising burden of kidney cancer, necessitating early detection and treatment strategies.

Advancements in medical research and technology have led to the development of novel therapeutics and diagnostics for kidney cancer, expanding treatment options and improving patient survival rates. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors, disrupt specific pathways involved in tumor growth and progression, offering personalized treatment approaches based on molecular profiling and genetic mutations.

Immunotherapy has emerged as a promising treatment modality for kidney cancer, harnessing the body's immune system to target and destroy cancer cells. Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, have demonstrated significant efficacy in patients with advanced or metastatic RCC, leading to improved survival outcomes and durable responses.

Advancements in diagnostic imaging techniques, including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound, enable accurate staging and monitoring of kidney cancer, guiding treatment decisions and patient management. Biomarker tests, such as circulating tumor DNA (ctDNA) analysis and gene expression profiling, provide valuable insights into tumor biology, prognosis, and treatment response, facilitating personalized medicine approaches in kidney cancer care.

Collaborative efforts between healthcare providers, research institutions, pharmaceutical companies, and regulatory agencies drive innovation and clinical development in the kidney cancer therapeutics and diagnostics market. Clinical trials evaluating novel agents, combination therapies, and predictive biomarkers further expand the treatment landscape and improve patient outcomes in kidney cancer.

The global kidney cancer therapeutics and diagnostics market is poised for growth, fueled by advancements in research, technology, and collaborative initiatives aimed at addressing the unmet needs of patients with kidney cancer. As the understanding of tumor biology and immune mechanisms continues to evolve, the development of innovative therapies and diagnostic tools holds promise for improving outcomes and quality of life for individuals affected by kidney cancer.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Cancer Type
    2. Market Snapshot, By Component
    3. Market Snapshot, By Region
  4. Global Kidney Cancer Therapeutics & Diagnostics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological Advancements
        2. Increasing Incidence of Kidney Cancer
        3. Growing Pipeline of Novel Therapies
      2. Restraints
        1. High Cost of Treatment
        2. Limited Efficacy of Current Therapies
        3. Regulatory Challenges
      3. Opportunities
        1. Personalized Medicine
        2. Emerging Markets
        3. Advancements in Biomarker Discovery
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Kidney Cancer Therapeutics & Diagnostics Market, By Cancer Type, 2021 - 2031 (USD Million)
      1. Clear cell RCC
      2. Papillary RCC
      3. Chromophobe RCC
      4. Urothelial carcinoma/Transitional cell carcinoma
      5. Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
    2. Global Kidney Cancer Therapeutics & Diagnostics Market, By Component, 2021 - 2031 (USD Million)
      1. Drugs
        1. Therapeutic Class
          1. Targeted Therapy
          2. Immunotherapy
          3. Other Therapeutic Class
        2. By Pharmacologic Class
          1. Angiogenesis Inhibitors
          2. Monoclonal Antibodies
          3. mTOR Inhibitors
          4. Cytokine Immunotherapy (IL-2)
      2. Diagnostics
        1. Biopsy
        2. Imaging Tests
        3. Blood Tests
        4. Other Diagnostics
    3. Global Kidney Cancer Therapeutics & Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Amgen Inc.
      2. Bayer AG
      3. F. Hoffmann-La Roche
      4. ABBOTT LABORATORIES
      5. BRISTOL-MYERS SQUIBB COMPANY
  7. Analyst Views
  8. Future Outlook of the Market